Chronic myeloid leukaemia – CML – is difficult to monitor and manage using traditional solutions. New RNA-based assays are hitting the market to make monitoring more effective ...

Icon has reached a preliminary agreement with Intel to use the Intel Pharma Analytics Platform in clinical trials. Launched in 2013, the Intel platform can continuously monitor and collect ...